Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Bolsa de Madrid  >  Grifols SA       ES0171996012

GRIFOLS SA
Mes dernières consult.
Most popular
 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials (€)
Sales 2017 4 343 M
EBIT 2017 1 118 M
Net income 2017 638 M
Debt 2017 5 586 M
Yield 2017 1,55%
Sales 2018 4 565 M
EBIT 2018 1 227 M
Net income 2018 739 M
Debt 2018 5 188 M
Yield 2018 1,78%
P/E ratio 2017 25,29
P/E ratio 2018 21,73
EV / Sales2017 4,61x
EV / Sales2018 4,30x
Capitalization 14 436 M
More Financials
Company
Grifols SA is a vertically integrated global producer of plasma derivatives.Its activities include sourcing raw material, manufacturing various plasma derivative products and selling and distributing final products to healthcare providers.The company operates through the following segments: ... 
Sector
Pharmaceuticals
Calendar
11/07Earnings Release
More about the company
Surperformance© ratings of Grifols SA
Trading Rating : Investor Rating :
More Ratings
Latest news on GRIFOLS SA
08/02 GRIFOLS : Select American Red Cross Blood Donations Screened for Babesia Parasit..
08/01 GRIFOLS : Adds Therapeutic Drug Monitoring Testing Services
07/28 GRIFOLS : increases its revenues by 12.3% to EUR 2,192 million driven by growth ..
07/28 GRIFOLS : increases its revenues by 12.3% to EUR 2,192 million driven by growth ..
07/17 Global Disposable Plastic Blood Bag Market 2017 - Wego, TERUMO, Fresenius, Gr..
07/06 GRIFOLS : opens new lines of research with the acquisition of a 44% stake in Gig..
07/05 GRIFOLS : opens new lines of research with the acquisition of a 44% stake in Gig..
06/29 GRIFOLS : voluntarily discloses transfers of value
06/27 GRIFOLS : Araclon Biotech initiates phase II clinical trials of its Alzheimer's ..
06/26 Global Disposable Plastic Blood Bag Market 2017 - Wego, TERUMO, Fresenius, Gr..
More news
Sector news : Biopharmaceuticals
08/18DJCorrection to Biogen Treads Tricky Path Between Politicians, Investors Articl..
08/18DJMERCK AND : Scientists, Out $12 Million, Sue Delaware Over Seizure of Their Stoc..
08/18DJASTRAZENECA : FDA Approves AstraZeneca's Ovarian Cancer Treatment Lynparza Table..
08/17 FDA expands use of AstraZeneca/Merck ovarian cancer drug
08/17 Drugmaker Hikma trims sales forecasts, shares fall
More sector news : Biopharmaceuticals
News from SeekingAlpha
2016 Midday Gainers / Losers
2015 Tracking John Paulson's Paulson & Company Portfolio - Q3 2015 Update
2015 TiGenix Achieves First Ever Success In Allogeneic Stem Cell Phase 3 Trial
2015 Tracking John Paulson's Paulson & Company Portfolio - Q2 2015 Update
2015 Tracking John Paulson's Paulson & Company Portfolio - Q1 2015 Update
Income Statement Evolution
Consensus
 
Mean consensus HOLD
Number of Analysts 23
Average target price 24,6 €
Spread / Average Target 5,5%
EPS Revisions
Managers
NameTitle
Raimon Grifols Roura Joint Chief Executive Officer & Director
Victor Grifols Deu Joint Chief Executive Officer & Executive Director
Víctor Grifols Roura Non-Executive Chairman
Alfredo Arroyo Guerra Chief Financial Officer & Vice President
Vicente Blanquer Torre Vice President-Quality, Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
GRIFOLS SA16 977
BIOGEN7.82%59 575
CSL LIMITED28.08%45 880
ALEXION PHARMACEUTICALS9.03%29 773
GRIFOLS SA23.33%16 977
BIOMARIN PHARMACEUTICAL-2.32%14 183